Article
Recombinant mutated human TNF in combination with chemotherapy for stage IIIB/IV non-small cell lung cancer: a randomized, phase III study.
Scientific reports - 21 Apr 2015
Ma Xiaowen, Song Yang, Zhang Kuo, Shang Lei, Gao Yuan, Zhang Wei, Xue Xiaochang, Jia Huimin, Geng Jian, Zhou Wei, Dang Yazheng, Li Enxiao, Ti Xinyu, Fan Fulin, Zhang Yingqi, Li Meng
Abstract excerpt
Tumor necrosis factor (TNF), an anti-angiogenic agent in cancer treatment, is limited to isolated limb perfusion due to systemic toxicities. We previously prepared a TNF mutant (rmhTNF) that significantly improved responses in lung cancer patients and exhibited a promising safety profile in phase I and II studies. To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.